Clonal Hematopoiesis and Heart Disease: What the Link Means
Clonal hematopoiesis is an age-associated blood signal that cohort studies link to higher heart attack and stroke risk. It is not a diagnosis and not guideline screening.
Medically reviewed by Rhonda Collins, FNP-C | Mito Health on August 27, 2026.
Clonal hematopoiesis (CH), sometimes called CHIP, is a measurable, age-associated change in the blood that cohort studies have linked to a higher risk of heart attack and stroke. It is not a diagnosis, and it is not a guideline-endorsed population screening test. The evidence is observational, which means an association has been observed but causation has not been proven, and detecting CH does not by itself show that acting on it changes outcomes. What CH can do is add an inflammatory, aging-related risk signal that a standard lipid panel does not capture, which is why some people discuss it with their doctor alongside the rest of their cardiovascular workup.
What does clonal hematopoiesis have to do with heart disease?
Clonal hematopoiesis happens when a blood-forming (hematopoietic) stem cell acquires a mutation that gives it a growth advantage, so it expands into a larger population of blood cells that all carry that mutation. This becomes more common with each decade of life past 40 and is independent of ancestry. Crucially, it is an inflammatory process. The same mutated clones that are linked to blood cancers are also linked to cardiovascular risk (Jaiswal S and Ebert BL, Science, 2019;366:eaan4673).
The proposed biological link is inflammation in the artery wall. CH-mutated immune cells, such as monocytes and macrophages carrying mutations in genes like TET2, can be more inflammatory and appear to accelerate atherosclerosis, the buildup of plaque in arteries. This mechanism was described in the large cohort analyses that first connected CH to cardiovascular events (Jaiswal S et al., New England Journal of Medicine, 2014;371:2488, and 2017;377:111; Genovese G et al., New England Journal of Medicine, 2014;371:2477). These studies show a consistent association. They do not prove that CH causes heart disease in any individual, and they do not establish that lowering CH changes a person’s cardiovascular outcome.
How much does clonal hematopoiesis raise cardiovascular risk?
The reported associations are substantial, but they come from different study designs and different populations, so they are not interchangeable. Hazard ratios (HR) come from cohorts followed over time. The odds ratio (OR) comes from case-control studies, which compare people who already had an event against those who did not. These are associations, not individual predictions, and not causation.
Cardiovascular event | Who the estimate describes | Reported association | 95% confidence interval |
|---|---|---|---|
Coronary heart disease | CH carriers | ~1.9x (HR 1.9) | 1.4 to 2.7 |
Early-onset heart attack (age 50 or under) | CH carriers | ~4x (OR 4.0) | 2.4 to 6.7 |
Coronary heart disease | Carriers of the JAK2 V617F mutation only | ~12x (HR 12.0) | 3.8 to 38.4 |
Ischemic stroke | CH carriers | ~2.6x (HR 2.6) | 1.4 to 4.8 |
Compared with non-carriers. Association does not prove causation. Coronary heart disease, early-onset heart attack, and the JAK2-specific estimate from Jaiswal S et al., New England Journal of Medicine 2017;377:111; ischemic stroke from Jaiswal S et al., New England Journal of Medicine 2014;371:2488. The JAK2 V617F estimate covers a small subset of CH carriers, so it is not the risk for CH generally.
The same body of work links CH to a roughly 12.9-fold higher risk of blood cancer (hematologic cancer HR = 12.9; 95% CI 5.8 to 28.7; Genovese G et al., New England Journal of Medicine 2014;371:2477), which is why a CH result is relevant beyond the heart. Two nuances matter for interpretation. Detectable CH mutations are rare before age 40 and rise steeply with age, and in adults aged 80 and older the presence of CH did not associate with higher mortality in one cohort (van Zeventer IA et al., Blood Advances, 2021;5(8):2115). Context, including age and the specific gene involved, changes what a result means.
Why might someone with no traditional risk factors still be at risk?
Standard risk factors such as high LDL cholesterol, high blood pressure, smoking, and diabetes explain a large share of cardiovascular events, but not all of them. A meaningful minority of patients have no identified traditional risk factor at the time of their event. Roughly 1 in 4 heart attack patients have no known standard risk factors (Paul G et al., Global Heart, 2023;18(1)), and about 1 in 5 stroke patients present with no known risk factors (Beharry J et al., European Stroke Journal, 2025).
CH is one of the newer, non-traditional signals researchers are studying to help explain part of that residual risk. It reflects an inflammatory, aging-related process rather than a lipid problem, so it can be present in someone whose cholesterol and blood pressure look reassuring. This is an area of active research, not settled clinical practice, and a CH result should be read as one input among many rather than a verdict.
What should you do if clonal hematopoiesis is detected?
A CH result is a prompt for a conversation with your doctor, not an emergency and not a diagnosis of heart disease. Reasonable, evidence-aligned steps focus on the modifiable risk you can actually act on today:
- Discuss the result with your doctor in the context of your age, family history, symptoms, and the specific gene and VAF on your report.
- Tighten management of traditional risk factors. Blood pressure, LDL cholesterol and ApoB, blood sugar, smoking, weight, and physical activity remain the highest-yield levers, and they matter more, not less, if an additional risk signal is present.
- Consider cardiology follow-up if your overall risk picture warrants it, so surveillance and prevention can be individualized.
- Repeat testing on the interval your report recommends, since CH can change over time and the clinically relevant question is often the trend, not a single snapshot.
On treatment specifically, keep expectations grounded. Anti-inflammatory drugs have been shown to reduce CH-related activity in exploratory research, but this is early and exploratory only. It is not a treatment recommendation, and there is no established therapy that treats CH to lower cardiovascular risk. The proven actions today are the modifiable risk factors above.
How does a CH test fit with the rest of your heart bloodwork at Mito?
CardioHemeRISK is a prescription-only blood test that looks for CH mutations across 15 genes and returns a risk-oriented score. It costs $899.64 ($642.60 for Mito members), and is HSA and FSA eligible. Ordering runs through a telehealth partner: you request the test, a clinician reviews and orders it if appropriate, a mobile phlebotomist collects the sample, and your score and personalized action items are delivered back through the telehealth partner.
The Mito-distinctive value is integration. A CH signal is most useful next to the rest of your cardiovascular picture, so you can order and trend ApoB, Lp(a), LDL cholesterol, and inflammation markers like hs-CRP in one place, ask follow-up questions through Mito Concierge, and book a 1:1 consultation to turn results into a plan. That way an inflammatory, aging-related signal is read alongside the lipid and blood-pressure drivers it does not replace.
See what a CH blood test covers. Not sure where to start? Take the quiz and build your cardiovascular workup first.
Clonal hematopoiesis and heart disease questions
Does clonal hematopoiesis cause heart disease? No claim of causation is established. Cohort studies show CH is associated with higher heart attack and stroke risk, and there is a plausible inflammatory mechanism, but the evidence is observational. Association is not the same as causation.
Is CH testing recommended screening for heart disease? No. CH is a promising, measurable, age-associated signal, but it is not a guideline-endorsed population screening test. Standard cardiovascular risk assessment remains the foundation.
What counts as a high-risk CH result for the heart? Larger clones, with a variant allele frequency above 10 percent, carry the strongest reported associations. Your report specifies the genes and VAF, which your doctor interprets alongside your other risk factors.
If my cholesterol is normal, can I still have elevated CH? Yes. CH reflects an inflammatory, aging-related process that is separate from lipids, so it can be present when cholesterol and blood pressure look reassuring.
Can anything treat CH to lower heart risk? There is no established treatment for CH to reduce cardiovascular risk. Anti-inflammatory drugs have reduced CH-related activity in exploratory research only. The proven steps are managing traditional risk factors with your doctor.
Related reading
- What Is Clonal Hematopoiesis (CHIP)?
- Clonal Hematopoiesis (CHIP): A Complete Guide
- CHIP Testing vs Standard Cardiovascular Risk Assessment
- Silent Heart Attack: Risk Factors With No Warning Signs
- Apolipoprotein B (ApoB): What Your Level Means
Medical disclaimer
This guide is for informational purposes only. It does not diagnose heart disease or clonal hematopoiesis, and it does not replace medical care. CardioHemeRISK is a prescription-only laboratory test, not a diagnosis, and it does not assess inherited genetic risk or include every gene associated with these risks. The risk associations described here come from observational studies, so they show association rather than causation. A qualified clinician should interpret any result in the context of your symptoms, history, examination, and other testing.
